{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T04:43:54Z","timestamp":1791089034466,"version":"4.1.0"},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["NDT"],"DOI":"10.2147\/ndt.s30160","type":"journal-article","created":{"date-parts":[[2014,2,4]],"date-time":"2014-02-04T01:04:52Z","timestamp":1391475892000},"page":"249","source":"Crossref","is-referenced-by-count":14,"title":["Gabapentin enacarbil for the treatment of moderate to severe primary restless legs syndrome (Willis-Ekbom disease): 600 or 1,200 mg dose?"],"prefix":"10.2147","author":[{"given":"Akito","family":"Kume","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2014,2]]},"container-title":["Neuropsychiatric Disease and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=18883","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,10,30]],"date-time":"2016-10-30T22:13:11Z","timestamp":1477865591000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.dovepress.com\/gabapentin-enacarbil-for-the-treatment-of-moderate-to-severe-primary-r-peer-reviewed-article-NDT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/ndt.s30160","relation":{},"ISSN":["1176-6328"],"issn-type":[{"value":"1176-6328","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}